{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T08:55:06Z","timestamp":1656579306472},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T00:00:00Z","timestamp":1392249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s12471-014-0525-0","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T10:20:10Z","timestamp":1392200410000},"page":"167-173","source":"Crossref","is-referenced-by-count":5,"title":["Everolimus- and sirolimus-eluting stents in patients with and without ST-segment elevation myocardial infarction"],"prefix":"10.1007","volume":"22","author":[{"given":"M. A.","family":"Velders","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. J.","family":"van Boven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. C.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W. J.","family":"van \u2019t Hof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Quer\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"Hofma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,13]]},"reference":[{"key":"525_CR1","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1161\/CIRCULATIONAHA.108.826479","volume":"119","author":"AJ Kirtane","year":"2009","unstructured":"Kirtane AJ, Gupta A, Iyengar S, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198\u2013206.","journal-title":"Circulation"},{"key":"525_CR2","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/archinternmed.2012.758","volume":"172","author":"G Luca De","year":"2012","unstructured":"De Luca G, Dirksen MT, Spaulding C, et al. Drug-eluting vs bare-metal stents in primary angioplasty: a pooled patient-level meta-analysis of randomized trials. Arch Intern Med. 2012;172:611\u201321.","journal-title":"Arch Intern Med"},{"key":"525_CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jcin.2010.11.004","volume":"4","author":"B Brodie","year":"2011","unstructured":"Brodie B, Pokharel Y, Fleishman N, et al. Very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction: a 15-year single-center experience. J Am Coll Cardiol Intv. 2011;4:30\u20138.","journal-title":"J Am Coll Cardiol Intv"},{"key":"525_CR4","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1161\/CIRCULATIONAHA.107.762047","volume":"118","author":"G Nakazawa","year":"2008","unstructured":"Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138\u201345.","journal-title":"Circulation"},{"key":"525_CR5","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1093\/eurheartj\/ehn553","volume":"31","author":"AK Hassan","year":"2010","unstructured":"Hassan AK, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J. 2010;31:1172\u201380.","journal-title":"Eur Heart J"},{"key":"525_CR6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jacc.2011.02.023","volume":"58","author":"PC Smits","year":"2011","unstructured":"Smits PC, Kedhi E, Royaards KJ, et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERT\u00c9 stent in all-comers: a randomized open label trial). J Am Coll Cardiol. 2011;58:11\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"525_CR7","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jacc.2012.07.004","volume":"60","author":"LO Jensen","year":"2012","unstructured":"Jensen LO, Thayssen P, Christiansen EH, et al. 2-year patient-related versus stent-related outcomes: the SORT OUT IV (Scandinavian Organization for Randomized Trials With Clinical Outcome IV) Trial. J Am Coll Cardiol. 2012;60:1140\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"525_CR8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jacc.2011.06.027","volume":"58","author":"RA Byrne","year":"2011","unstructured":"Byrne RA, Kastrati A, Massberg S, et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol. 2011;58:1325\u201331.","journal-title":"J Am Coll Cardiol"},{"key":"525_CR9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1161\/CIRCULATIONAHA.112.104059","volume":"126","author":"T Kimura","year":"2012","unstructured":"Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation. 2012;126:1225\u201336.","journal-title":"Circulation"},{"key":"525_CR10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2011.07.031","volume":"58","author":"KW Park","year":"2011","unstructured":"Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial. J Am Coll Cardiol. 2011;58:1844\u201354.","journal-title":"J Am Coll Cardiol"},{"key":"525_CR11","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jacc.2012.01.073","volume":"60","author":"SH Hofma","year":"2012","unstructured":"Hofma SH, Brouwer J, Velders MA, et al. Second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction. 1-year results of the randomized XAMI (XienceV Stent vs. Cypher Stent in Primary PCI for Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2012;60:381\u20137.","journal-title":"J Am Coll Cardiol"},{"key":"525_CR12","doi-asserted-by":"crossref","unstructured":"Velders MA, Hofma SH, Brouwer J, et al. Two-year results of an open-label randomized comparison of everolimus-eluting stents and sirolimus-eluting stents. PLoS ONE. 2013:e64424. doi: 10.1371\/journal.pone.0064424 .","DOI":"10.1371\/journal.pone.0064424"},{"key":"525_CR13","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","volume":"115","author":"DE Cutlip","year":"2007","unstructured":"Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344\u201351.","journal-title":"Circulation"},{"key":"525_CR14","doi-asserted-by":"crossref","first-page":"b2393","DOI":"10.1136\/bmj.b2393","volume":"338","author":"JA Sterne","year":"2009","unstructured":"Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi: 10.1136\/bmj.b2393 .","journal-title":"BMJ"},{"key":"525_CR15","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","volume":"377","author":"GW Stone","year":"2011","unstructured":"Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193\u2013204.","journal-title":"Lancet"},{"key":"525_CR16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jcin.2011.06.018","volume":"4","author":"D Planer","year":"2011","unstructured":"Planer D, Smits PC, Kereiakes DJ, et al. Comparison of everolimus- and paclitaxel-eluting stents in patients with acute and stable coronary syndromes: pooled results from the SPIRIT (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (A Trial of Everolimus-Eluting Stents and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice) Trials. J Am Coll Cardiol Intv. 2011;4:1104\u201315.","journal-title":"J Am Coll Cardiol Intv"},{"key":"525_CR17","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/S0140-6736(12)61223-9","volume":"380","author":"M Sabate","year":"2012","unstructured":"Sabate M, Cequier A, I\u00f1iguez A, et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012;380:1482\u201390.","journal-title":"Lancet"},{"key":"525_CR18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jcin.2011.11.005","volume":"5","author":"B Kalesan","year":"2012","unstructured":"Kalesan B, Stefanini GG, R\u00e4ber L, et al. Long-term comparison of everolimus- and sirolimus-eluting stents in patients with acute coronary syndromes. J Am Coll Cardiol Intv. 2012;5:145\u201354.","journal-title":"J Am Coll Cardiol Intv"},{"key":"525_CR19","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","volume":"123","author":"K Kolandaivelu","year":"2011","unstructured":"Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation. 2011;123:1400\u20139.","journal-title":"Circulation"},{"key":"525_CR20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","volume":"52","author":"M Joner","year":"2008","unstructured":"Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333\u201342.","journal-title":"J Am Coll Cardiol"},{"key":"525_CR21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jcin.2010.10.007","volume":"4","author":"C Spaulding","year":"2011","unstructured":"Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). J Am Coll Cardiol Intv. 2011;4:14\u201323.","journal-title":"J Am Coll Cardiol Intv"},{"key":"525_CR22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1001\/jama.2012.10065","volume":"308","author":"L R\u00e4ber","year":"2012","unstructured":"R\u00e4ber L, Kelb\u00e6k H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA. 2012;308:777\u201387.","journal-title":"JAMA"},{"key":"525_CR23","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33:1214\u201322.","journal-title":"Eur Heart J"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-014-0525-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12471-014-0525-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-014-0525-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T15:30:48Z","timestamp":1553700648000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12471-014-0525-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,13]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["525"],"URL":"https:\/\/doi.org\/10.1007\/s12471-014-0525-0","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,13]]}}}